Let's break down RPG Life Sciences Limited (RPGLIFE) — from its financial performance to how the market is valuing the stock.
RPG Life Sciences Limited Revenue Trend
RPG Life Sciences Limited's top line grew 8.3% to ₹708 Cr in FY2026, compared to ₹653 Cr in FY2025.
On a 10-year view, revenue grew at 9.7% per year from ₹279 Cr to ₹708 Cr. Respectable, though not in the high-growth bracket.
In terms of scale, RPG Life Sciences Limited's ₹708 Cr in annual revenue positions it as a smaller pharmaceuticals company.
It's been 7 years of continuous revenue growth for RPG Life Sciences Limited — a pattern worth noting.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹708 Cr | +8.3% |
| FY2025 | ₹653 Cr | +12.3% |
| FY2024 | ₹582 Cr | +13.5% |
| FY2023 | ₹513 Cr | +16.5% |
| FY2022 | ₹440 Cr | — |
View RPG Life Sciences Limited's full 10-year revenue trend with CAGR analysis →
RPG Life Sciences Limited Profitability
Profitability was under pressure with net income dropping 37.1% to ₹115 Cr in FY2026.
Profitability per rupee of revenue dipped, with net margin at 16.3% against 28.0% in FY2025.
On a per-share basis, diluted earnings were ₹69.64 in FY2026 versus ₹110.80 in FY2025.
Is RPG Life Sciences Limited Undervalued
RPG Life Sciences Limited shares are currently trading at ₹2,756.80.
Craytheon calculates intrinsic value using the P/E Ratio and EPS Growth models. Both appear in the Valuation Models cards below.
Valuation Models
RPG Life Sciences Limited Shareholding Pattern
Promoter holding has remained stable at 73.0% over the past 4 quarters, indicating confidence in the company's direction.
FII holding stands at 0.9%, down from 1.1% in the year-ago quarter.
As of June 2026, DIIs own 8.7% of the company — up from 6.7% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 73.0% | 0.9% | 8.7% | 17.4% |
| Mar 2026 | 73.0% | 0.9% | 7.5% | 18.7% |
| Dec 2025 | 73.0% | 1.0% | 7.0% | 19.0% |
| Sep 2025 | 73.0% | 1.1% | 6.7% | 19.2% |
Track quarterly shareholding changes for RPG Life Sciences Limited →
RPG Life Sciences Limited Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹7.93B (up 20.6% YoY from ₹6.58B).
Top categories: Cash & ST Investments (29.5%), Property, Plant & Equipment (26.7%), Inventories (15.6%).
Of the ₹7.93B in liabilities and equity, 76.3% is shareholder equity, 2.5% is interest-bearing debt, and 21.2% is operating liabilities. Notable shift: Other Liabilities is up 47.3% YoY (₹478.90M → ₹705.60M).
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 2.34B |
| Receivables | 1.17B |
| Inventories | 1.24B |
| Property, Plant & Equipment | 2.12B |
| Investments | 10.10M |
| Intangibles & Goodwill | 48.40M |
| Other Assets | 1.01B |
| Category | Value |
|---|---|
| Equity | 6.05B |
| Short-term Debt | 66.70M |
| Long-term Debt | 133.30M |
| Trade Payables | 972.50M |
| Other Liabilities | 705.60M |
RPG Life Sciences Limited — The Bottom Line
Bringing the key threads together for RPG Life Sciences Limited (RPGLIFE) as a pharmaceuticals investment opportunity.
Revenue of ₹708 Cr in FY2026, up 8.3% year-over-year.
Long-term revenue has been compounding at 9.7% annually over 10 years.
The company is profitable, with a net margin of 16.3% and net income of ₹115 Cr.
Unlock Full Analysis
Craytheon's full analysis of RPG Life Sciences Limited goes deeper: three valuation models, growth metrics, and 10 years of financial data.